These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 25572840

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Inflammatory bowel disease: an overview].
    Herrlinger K.
    Med Monatsschr Pharm; 2013 Nov; 36(11):402-8; quiz 409. PubMed ID: 24640117
    [Abstract] [Full Text] [Related]

  • 25. Current pharmacotherapy for inflammatory bowel disease.
    McKaig BC, Stack WA.
    Expert Opin Pharmacother; 1999 Nov; 1(1):3-14. PubMed ID: 11249561
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [Abstract] [Full Text] [Related]

  • 28. A review of current evidence allied to step-up and top-down medication therapy in inflammatory bowel disease.
    Salahudeen MS.
    Drugs Today (Barc); 2019 Jun; 55(6):385-405. PubMed ID: 31250843
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies.
    Liu J, Di B, Xu LL.
    Cytokine Growth Factor Rev; 2023 Jun; 71-72():1-12. PubMed ID: 37455149
    [Abstract] [Full Text] [Related]

  • 31. JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease.
    Macaluso FS, Rodríguez-Lago I.
    Curr Drug Metab; 2020 Jun; 21(4):247-255. PubMed ID: 32156234
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management].
    Bakulin IG, Skalinskaya MI, Maev IV, Skazyvaeva EV, Zhuravleva MS, Gaikovaya LB, Bakulina NV, Ermakov AI, Alekseenko ES, Ivanova KN, Solovev MV.
    Ter Arkh; 2021 Aug 15; 93(8):841-852. PubMed ID: 36286877
    [Abstract] [Full Text] [Related]

  • 35. Nanomedicine-mediated drug delivery for potential treatment of inflammatory bowel disease: a narrative review.
    Ardekani ZM, Lorenzo-Leal AL, Bach H.
    Nanomedicine (Lond); 2024 Jan 15; 19(2):163-179. PubMed ID: 38284393
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Regulation of inflammatory bowel disease by amino acids].
    Sun Q, Wu H, Li S, Sun Z.
    Sheng Wu Gong Cheng Xue Bao; 2022 Jun 25; 38(6):2128-2138. PubMed ID: 35786467
    [Abstract] [Full Text] [Related]

  • 38. Topical delivery of steroids in inflammatory bowel disease.
    Girlich C, Scholmerich J.
    Curr Drug Deliv; 2012 Jul 25; 9(4):345-9. PubMed ID: 22762277
    [Abstract] [Full Text] [Related]

  • 39. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH, Munck LK.
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar 25; 4(3):160-70. PubMed ID: 17339853
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.